Intuitive Surgical (ISRG)

Executive Summary

Intuitive Surgical (ISRG) remains the dominant player in robotic-assisted surgery, with its da Vinci platform serving as the cornerstone of minimally invasive procedures globally. The company's high-margin recurring revenue model—driven by recurring instrument, accessory, and service contracts—provides predictable cash flows and supports continued investment in innovation. With a $162B market cap and a growing installed base, Intuitive Surgical is well-positioned to expand into adjacent markets such as bronchoscopy via the Ion system. The company's strong competitive moat, deep clinical adoption, and robust financial profile underpin its long-term growth outlook.

Upcoming Catalysts (preview)

• Q1 2027FDA approval of next-generation da Vinci system (da Vinci 5 or SP expansion)80% success
• Q4 2026Ion bronchoscopy system adoption acceleration and potential label expansion70% success
• Q3 2026New indication or clinical data for da Vinci in general surgery or urology75% success